These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35451880)

  • 1.
    Gupta A; Malik S; Kaminski M; Landman D; Quale JM
    Microb Drug Resist; 2022 Apr; 28(4):419-424. PubMed ID: 35451880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.
    Cohen Stuart J; Leverstein-Van Hall M; Kortmann W; Verlind J; Mulder F; Scharringa J; Fluit A; Ekkelenkamp M
    Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):2021-2025. PubMed ID: 30117050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
    Docobo-Pérez F; López-Cerero L; López-Rojas R; Egea P; Domínguez-Herrera J; Rodríguez-Baño J; Pascual A; Pachón J
    Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial.
    Stewart AG; Bauer MJ; Butkiewicz D; Hinton A; Henderson A; Harris PNA; Paterson DL
    Int J Antimicrob Agents; 2023 Aug; 62(2):106858. PubMed ID: 37211261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favourable effect of clavulanic acid on the minimum inhibitory concentrations of cefixime and ceftibuten in ESBL-producing Escherichia coli and Klebsiella pneumoniae.
    Martinez-Guerra BA; Xancal-Salvador LF; Esteban-Kenel V; Tello-Mercado AC; Bobadilla-Del-Valle M; Sifuentes-Osornio J; Ponce-de-Leon A; Gonzalez-Lara MF
    J Glob Antimicrob Resist; 2024 Sep; 38():212-215. PubMed ID: 38945364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
    Rossi B; Soubirou JF; Chau F; Massias L; Dion S; Lepeule R; Fantin B; Lefort A
    Antimicrob Agents Chemother; 2016 Jan; 60(1):424-30. PubMed ID: 26525800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing
    Al-Tamimi M; Abu-Raideh J; Albalawi H; Shalabi M; Saleh S
    Microb Drug Resist; 2019 Oct; 25(8):1132-1141. PubMed ID: 31107146
    [No Abstract]   [Full Text] [Related]  

  • 9. [Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae].
    de Cueto M; Hernández JR; López-Cerero L; Morillo C; Pascual A
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):613-6. PubMed ID: 17194386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is There an Association Between Use of Amoxicillin-Clavulanate and Resistance to Third-Generation Cephalosporins in Klebsiella pneumoniae and Escherichia coli at the Hospital Level?
    Marquet A; Vibet MA; Caillon J; Javaudin F; Chapelet G; Montassier E; Batard E
    Microb Drug Resist; 2018 Sep; 24(7):987-994. PubMed ID: 29489447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments.
    Skarp KP; Shams A; Montelin H; Lagerbäck P; Tängdén T
    Int J Antimicrob Agents; 2019 Jan; 53(1):74-79. PubMed ID: 30236958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of
    Karlowsky JA; Wise MG; Hackel MA; Pevear DC; Moeck G; Sahm DF
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0093422. PubMed ID: 36286518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: effect of large inocula.
    Medeiros AA; Crellin J
    Pediatr Infect Dis J; 1997 Mar; 16(3 Suppl):S49-55. PubMed ID: 9076836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disc diffusion-based screening tests for extended-spectrum beta-lactamases in Haemophilus influenzae.
    Tristram SG; Bozdogan B; Appelbaum PC
    J Antimicrob Chemother; 2005 Apr; 55(4):570-3. PubMed ID: 15728142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology.
    Queenan AM; Foleno B; Gownley C; Wira E; Bush K
    J Clin Microbiol; 2004 Jan; 42(1):269-75. PubMed ID: 14715764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Efficacy of Six Alternative Antibiotics against Multidrug Resistant Escherichia Coli and Klebsiella Pneumoniae from Urinary Tract Infections.
    Chen YT; Ahmad Murad K; Ng LS; Seah JT; Park JJ; Tan TY
    Ann Acad Med Singap; 2016 Jun; 45(6):245-50. PubMed ID: 27412057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
    Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?
    Moland ES; Sanders CC; Thomson KS
    J Clin Microbiol; 1998 Sep; 36(9):2575-9. PubMed ID: 9705395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic
    Ract P; Compain F; Robin F; Decre D; Gallah S; Podglajen I
    J Med Microbiol; 2019 Sep; 68(9):1292-1298. PubMed ID: 31361213
    [No Abstract]   [Full Text] [Related]  

  • 20. Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of
    Chatwin CL; Hamrick JC; Trout REL; Myers CL; Cusick SM; Weiss WJ; Pulse ME; Xerri L; Burns CJ; Moeck G; Daigle DM; John K; Uehara T; Pevear DC
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0055221. PubMed ID: 34001510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.